Chemotherapy and Chemoprevention by Thiazolidinediones

Eleonore Fröhlich1,2 and Richard Wahl1

1 Internal Medicine, Department of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, Department IV, University of Tübingen, Otfried-Müllerstrasse 10, 72076 Tübingen, Germany
2 Center for Medical Research, Medical University of Graz, Stiftgutstrasse 24, 8010 Graz, Austria

Correspondence should be addressed to Richard Wahl; richard.wahl@med.uni-tuebingen.de

Received 31 May 2014; Revised 29 July 2014; Accepted 27 August 2014

Academic Editor: Viroj Boonyaratankornkit

Copyright © 2015 E. Fröhlich and R. Wahl. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thiazolidinediones (TZDs) are synthetic ligands of Peroxisome-Proliferator-Activated Receptor gamma (PPARγ). Troglitazone, rosiglitazone, and pioglitazone have been approved for treatment of diabetes mellitus type II. All three compounds, together with the first TZD ciglitazone, also showed an antitumor effect in preclinical studies and a beneficial effect in some clinical trials. This review summarizes hypotheses on the role of PPARγ in tumors, on cellular targets of TZDs, antitumor effects of monotherapy and of TZDs in combination with other compounds, with a focus on their role in the treatment of differentiated thyroid carcinoma. The results of chemopreventive effects of TZDs are also considered. Existing data suggest that the action of TZDs is highly complex and that actions do not correlate with cellular PPARγ expression status. Effects are cell-, species-, and compound-specific and concentration-dependent. Data from human trials suggest the efficacy of TZDs as monotherapy in prostate cancer and glioma and as chemopreventive agent in colon, lung, and breast cancer. TZDs in combination with other therapies might increase antitumor effects in thyroid cancer, soft tissue sarcoma, and melanoma.

1. Introduction

Glitazones, also called thiazolidinediones (TZDs), are five-membered carbon ring molecules containing two heteroatoms (nitrogen and sulfur). One carbonyl group in the thiazole at position 4 and another at position 2 make the heterocyclic compound a thiazolidine-2,4-dione [1]. TZDs are ligands of the Peroxisome Proliferator Activated Receptor gamma (PPARγ), a nuclear receptor inducing upregulation of specific genes that decrease insulin resistance, inflammation, VEGF-induced angiogenesis, proliferation, and leptin levels, inducing differentiation of adipocytes, and increasing adiponectin levels. This spectrum of actions led to the approval of TZDs for treatment of diabetes mellitus type II. TZDs differ according to the substitution at C5 (Figure 1).

Ciglitazone (CIGLI) is the prototype of all TZDs but has never been approved for medication of diabetes mellitus because its clinical activity was too weak. Troglitazone (TRO) was the first TZD approved for treatment of diabetes mellitus in 1997 [2]. The compound showed beneficial effects on glucose levels, insulin sensitivity, and free fatty acid concentration but was withdrawn from the market in 2000 due to severe hepatotoxicity. The second TZD, rosiglitazone (ROSI), has been banned in Europe and restricted in the USA because of increased cardiovascular morbidity. Also the use of pioglitazone (PIO) as the third TZD with antidiabetic action is restricted due to concerns about a potential facilitation of bladder cancer development. The fourth substance with an antidiabetic profile, rivoglitazone, is still under investigation [3]. Reasons for the troubled history of antidiabetic TZDs are manifold and appear to be due to the highly pleiotropic action of these PPARγ agonists and crosstalk of PPARγ with other signaling pathways.

In addition to diabetes mellitus treatment, ligands to PPARγ could also be exploited for treating other diseases, for instance, in cancer treatment. This idea originated from the finding that PPARγ is involved in cell proliferation and PPARγ expression levels change from normal to transformed tissues. Effects of PPARγ activation are ligand-specific. TZDs with potent PPARγ agonist activity can display, like...
rivoglitazone, strong antidiabetic activity, or, like efatutazone (EFA), predominantly antitumor effects. TZDs, such as netoglitazone, can also activate other PPARs and cause antitumor effects [4]. This review will focus on the effects of selective PPARγ TZDs in tumors.

2. Role of PPARγ Expression in Neoplasms

PPARγ expression compared to normal tissue tends to be increased in precursor lesions and differentiated tumors and decreased in the poorly differentiated cancers. This pattern has been reported for instance for gastric, ureteric, and breast cancer [5–7]. In ovarian cancer, however, PPARγ levels independent from tumor differentiation are increased [8]. Upregulation of PPARγ may be an early event in tumorigenesis and a marker for differentiated cancer lesions [9]. Methylation (silencing) of the PPARγ promotor, which is detected in 30% of colorectal tumors, however, correlated with poor prognosis [10]. Studies linking tumor prognosis and PPARγ expression were mainly based on immunohistochemical detection of the PPARγ antigen in paraffin-embedded tissue. Since antigenicity is low and may decrease during storage of the paraffin samples, the absence of PPARγ staining in archival tissues may be a false negative due to methodological problems [11].

Identification of the contribution of PPARγ to tumor development and progression is further complicated by crosstalk with other pathways. Akt phosphorylation in the endometrium, for instance, is directly regulated by PPARγ and indirectly through induction of PTEN by PPARγ, where PTEN decreases p-Akt via inhibition of PI3K [12].

3. Mechanism of Antitumor Action by TZDs

Although all TZDs are PPARγ ligands, the observed antitumor effects can only be explained in part by genomic PPARγ activation. Genomic activation is defined as the binding of a nuclear receptor to a response element, which activates the transcription of certain genes. The process is also termed transactivation. Another DNA-mediated effect is transrepression, which describes the binding of receptors to transcription factors (e.g., nuclear factor kappa B (NFκB) or activator protein 1 (AP-1)).

PPARγ ligands trigger a conformational change of the PPARγ receptor that attracts transcriptional coactivators of the steroid receptor coactivator family. Once activated by ligand binding, the PPARγ receptor forms heterodimers with the retinoid X-receptor and transcription is initiated. Transcriptional activation may result in decreased proliferation, migration and inflammation and increased differentiation.
and apoptosis (Figure 2). Inflammatory effects are usually mediated by transrepression [13].

Figure 2 illustrates the variety of pathways influenced by genomic activation of PPARγ by TZDs, resulting in downregulation of migration, proliferation, inflammation, and invasion and in upregulation of apoptosis. Common mechanisms involve influence on EGF signaling, cyclins, Ki-67, c-myc, cyclin-dependent kinases, p53 and PTEN expression, adhesion proteins, metalloproteinases, and cytokines [14–19].

Hormone-dependent cancers react through different mechanisms to TZDs depending on the hormone receptor status. In androgen-dependent prostate carcinoma, for instance, CIGLI downregulated aromatase activity, while in androgen-independent tumors proliferation was reduced [20].

Different TZDs may act by different mechanisms; while CIGLI downregulated cyclin D1 and upregulated p21 by PPARγ independent pathways, ROSI used PPARγ signaling to induce these effects in androgen-independent prostate carcinoma cells [21].

The description of all mechanisms of TZDs is beyond the scope of this review but one important signaling pathway for tumor cells and for surrounding tissue (tumor microenvironment) each illustrates the variety of PPARγ effects. Tumor biology is not only determined by tumor cells but to a high extent by properties of stromal cells in the tumor microenvironment. Among the diverse cells in the tumor stroma (endothelial cells, cancer-associated fibroblasts, leukocytes, myofibroblasts, and mesenchymal stem cells), tumor-associated macrophages play the most decisive role in tumor progression [22].

For tumor cells, signaling by Epidermal Growth Factor receptor (EGF-receptor, Figure 2) is highly relevant. The signaling cascade of the EGF-receptor involves the ERK cascade, consisting of Ras-Raf-MEK1/MEK2-ERK1/ERK2 and is seen in several cancer types [23]. ERK may phosphorylate PPARγ and reduce its genomic activity. This effect occurs in cancer cell lines and a variety of normal cells alike [24]. TRO, for example, was reported to bind to the EGF receptor and trigger its internalization in EGF-receptor transfected endothelial cells [25]. This action is an example of nongenomic effects of TZDs since no ligand binding to response element occurred.

Normal macrophages can transform into tumor-associated macrophages under stimulation of PPARγ ligands [26]. ROSI decreased activation of macrophages and thereby reduced inflammation in nondiabetic patients with symptomatic carotid artery stenosis [27]. In murine macrophages, these effects are mediated by interaction of PPARγ with NfκB [28]. In these effects, transrepression appears to be the main mechanism.
Finally, MEKI action by ROSI may lead to nuclear export and cytoplasmic retention of PPARγ and off-DNA interaction with proteins in MEKI-GFP and PPARγ (wild-type and mutant) cotransfected HEK-293 cells [29]. In this effect no genomic action of TZDs was involved.

4. Therapeutic Efficacy of TZDs in Specific Cancers

Decrease of cell proliferation, cytotoxicity, and proapoptotic effects induced by CIGLI, TRO, ROSI, and PIO has been reported in a variety of cell lines (sarcoma, melanoma, glioblastoma, breast carcinoma, colorectal cancer, gastric cancer, pancreatic cancer, prostate, bladder cancer, hepatic cancer, thyroid cancer, ovarian cancer, endometrial cancer, and lung cancer cells), which will not be listed in detail. Based on promising cellular action, animal experiments and clinical trials have been conducted in several common cancers.

EFA, which was developed as a chemostatic rather than an antidiabetic drug, has also been studied in some of these cancers. EFA is 500x more potent an activator of PPAR than TRO and 50x stronger than ROSI. EFA was studied in a preclinical murine model for breast cancer based on BRCA1 (Breast Cancer 1) deficiency. In the MMTV-CrBRCA1<sup>1/2</sup>−<sup>−</sup> model, exon II of the BRCA1 gene is deleted by Mouse Mammary Tumor Virus (MMTV)-Cre transgene. The deletion is accompanied by loss of one germline copy of TP53. EFA reduced the incidence of non-invasive and well-differentiated tumors in this model [30].

Cell proliferation and xenograft size of pancreatic, anaplastic thyroid, and colorectal cancer were reduced by EFA administration [31].

Based on these promising preclinical effects, phase I trials were initiated either as monotherapy or in combination with other compounds. After monotherapy with EFA, stable disease was induced in 10/22 patients with advanced liposarcoma [14]. A phase I study evaluating the combination of bexarotene with EFA in solid tumors is currently recruiting patients (NCT01504490).

The first trial of antitumor effects of the antidiabetic TZDs was conducted in three liposarcoma patients, where decrease of proliferation with TRO has been reported [32]. No beneficial effects, however, were obtained in a trial with ROSI in 9 liposarcoma patients [33]. Despite the negative outcome of this trial, another phase II trial on ROSI is ongoing (NCT00004180; http://www.cancer.gov/clinicaltrials/).

TZDs showed variable efficacy in studies of common cancers using xenograft and transgenic mouse models, in case studies and clinical trials (an overview is provided in Table 1).

4.1. Colorectal Cancer. Studies on human tumor samples support the hypothesis that PPARγ expression has protective effects in colorectal cancer [34]; patients with PPARγ expression usually showed a better prognosis [11]. Accordingly, reduction of β-catenin and PPARγ was associated with high numbers of tumor-associated macrophages, increased metastasis, and poor survival [35]. On the other hand, loss of function point mutations of the PPARγ gene and polymorphisms in PPARγ genes were encountered in 8% of colorectal carcinoma patients, but some studies on PPARγ expression in colorectal samples did not find any relation of PPARγ immunoreactivity and tumor parameters [36, 37]. The role of PPARγ activation in the progression of malignant lesions is questioned by the fact that heterozygous and homozygous intestinal-specific PPARγ deficiency promoted tumor formation [38]. This suggests that murine models might not be representative for the study of TZDs in colorectal cancer.

Consistent with the unclear role of PPARγ in tumor samples, TZDs showed variable effects in <i>vivo</i>. PPARγ activation inhibited xenograft growth in mice and PPARγ agonists reduced the number of aberrant cryptal foci in chemically induced inflammatory bowel disease in mice [39, 40]. On the other hand, PIO induced increased polyp numbers in mice with APC mutation, prone to developing colon adenoma (APC<sup>min</sup>), not in wild-type mice, suggesting that, under certain genetic conditions, TZDs could also promote colon cancer development [41]. The disparate results might be explained by <i>in vitro</i> studies in colon cancer cell lines showing that the level of PPARγ expression correlated to cells’ sensitivity to proliferation inhibition [42].

A phase II trial with TRO did not increase progression-free survival in 25 colorectal cancer patients [43].

4.2. Lung Cancer. PPARγ expression in well-differentiated lung adenocarcinoma was higher than in poorly differentiated tumors, suggesting that it promotes tumor formation but is not a marker for aggressive growth [44]. In another study, expression was linked to poor prognosis, showing the opposite trend [45]. ROSI decreased progression of chemically induced murine cancer model [46].

4.3. Breast Cancer. In breast cancer PPARγ mRNA levels did not correlate with nodal involvement and tumor grade but significantly lower PPARγ levels were seen in large metastatic tumors, patients with local recurrence and poor survival [47]. Despite the fact that samples of aggressive tumors showed increased PPARγ expression, TZDs displayed moderate positive effects in breast cancer models. ROSI reduced tumor growth in a chemically induced rat and in a syngenic murine tumor model [48, 49]. Both in patients with advanced breast carcinoma and in patients with early mammary cancer treatment with TZDs did not cause therapeutic effects [50, 51].

4.4. Prostate Cancer. In the majority of prostate cancers (73%), immunoreactivity and expression of PPARγ correlated inversely with tumor size and PSA levels [52]. Data obtained in prostate cancer xenografts as well as results from a phase II trial and a case report showed efficacy of PIO and TRO [53–55].

4.5. Glioblastoma. No correlation of PPARγ expression has been established with glioma [56]. Diabetes mellitus patients under TZD medication, however, showed lower incidence of high-grade glioma than the control group (patients with hip fractures), while survival of patients with glioma was similar.
Table 1: Relationship between protective role of PPARγ expression and efficacy of TZDs in therapy.

| Cancer type | Role of PPARγ | TZD | Experimental model | Result | Reference |
|-------------|---------------|-----|-------------------|--------|----------|
| Colon       | ⇐⇒            | PIO | Xenograft (HT-29) in mice with APC mutation, sc Azoxymethane-induced murine tumors | Increased tumor growth | [41] |
|             | ⇐⇒            | TRO | HT-29 xenografts, sc Metastatic colon cancer, 25 patients | Reduced tumor growth and metastasis | [40] |
| Lung        | ⇐⇒            | ROSI | Chemically-induced mouse model | Decrease in adenoma formation | [46] |
|             | ⇐⇒            | TRO | LMM3 injection into mice, sc Chemically induced rat model | Decreased tumor growth and incidence | [49] |
|             | ⇐⇒            | ROSI | Advanced chemotherapy breast refractory cancer, 22 patients | No CR or PR, 3 SD | [50] |
| Breast      | ⇐⇒            | TRO | Early stage breast cancer, 38 patients | No decrease in proliferation | [51] |
| Prostate    | ⇐⇒            | PIO | PC3 xenografts, sc. | Decrease of bone-invasive potential | [53] |
|             | ⇐⇒            | TRO | Advanced prostate carcinoma, 41 patients | Stabilization of PSA levels | [54] |
|             | ⇐⇒            | ROSI | Recurrent prostate carcinoma, 1 patient | Delayed increase of PSA levels | [55] |
| Glioma      | ⇐⇒            | PIO | LN229 orthotopic xenografts Chemorefractory glioma, 14 patients | Reduced tumor volume, invasion Disease stabilization (29%) | [58] [59] |
| Melanoma    | ⇐⇒            | CIGLI | A375 xenografts, sc. | Growth inhibition, pro-apoptotic effects | [62] |
| Thyroid     | ⇐⇒            | PIO | Transgenic mouse model (PPAR fusion protein/PTEN deletion) | Decreased tumor growth and metastasis | [106] |
|             | ⇐⇒            | ROSI | Transgenic mouse model (Thyroid hormone receptor-β negative) Metastatic thyroid cancer, 1 patient | Delayed progression Decrease in metastasis size | [107] [109] |

PPARγ expression on tumor progression: promotion: ⇑; protection: ⇐⇒; no effect: ⇐; CR: complete response; PR: partial response; SD: stable disease; sc: subcutaneous implantation of tumor cells.

in both groups [57]. Efficacy of PIO has been shown in glioma xenografts and in a phase II trial [58, 59].

4.6. Melanoma. No correlation of PPARγ expression and melanoma prognosis was seen [60]. In a cohort study of diabetes mellitus patients under PIO medication, an increased hazard ratio for melanoma (1.3) was reported [61]. It is not clear whether these data represent an increased incidence of tumors because the maximum duration of follow-up was <6 years after the initiation of PIO. Studies on monotherapy with TZDs in melanoma are limited: only CIGLI was reported to inhibit growth of melanoma xenografts [62].

Higher mRNA or protein expression in well-differentiated tumors compared to poorly differentiated tumors and tumors with poor prognosis is interpreted as protective effect of PPARγ in tumor development. In prostate cancer patients, protective effects of PPARγ and therapeutic effect of TZDs were in line (Table 1). In glioma samples, PPARγ expression was not linked to good prognosis but TZDs showed therapeutic efficacy.

5. Role of TZDs in Chemoprevention

While therapeutic efficacy of monotherapy with TZDs was relatively low, data obtained from meta-analysis of diabetes studies as well as in vitro data suggested that TZDs could be efficient in chemoprevention (Table 2).

5.1. Data from Diabetes Trials. Medication with TZDs for >1 year decreased the incidence of head and neck cancers by 40% and lung cancer by 33% in diabetes mellitus patients [63]. The reduction of lung cancer reached 75% in the African-American population. The reduction was specific for lung cancer, as prostate and colorectal cancer incidence was not changed. Of note, in this study, patients with preexisting malignancies were excluded. The largest meta-analysis on cancer incidence and cancer mortality included data of 46 trials. The number of malignancies was disclosed in 28/33 trials with ROSI and in 18/33 trials with PIO [64]. This meta-analysis reported less cancer cases (342 versus 457) in patients treated with TZDs compared to other medications. Overall, treatment with TZDs was associated with a significantly lower
incidence of cancer cases (Mantel-Haenszel odds ratio (MH-OR) 0.85; \( P = 0.027 \)). For ROSI this effect was significant for colorectal cancer (MH-OR 0.63; \( P = 0.03 \)). PIO treatment significantly reduced the incidence of breast cancer (MH-OR 0.28; \( P = 0.004 \)). An increase in the incidence of bladder cancer by PIO treatment was not seen (MH-OR 2.05; \( P = 0.12 \)), but cancer mortality was increased upon TZD treatment. Since this mortality most probably is due to preexisting cancers, the question remains whether treatment with TZDs could promote the growth of already existing malignant lesions.

### 5.2. In Vitro Differentiation Studies

Morphological differentiation (duct formation in collagen gels) increased in pancreatic carcinoma cells treated with TRO [65] and increases of villin and mucin mRNA were observed in colon cancer cell lines [66]. ROSI induced PTEN expression in Caco-2 cells and restored glandular morphogenesis [67]. It increased tyrosinase expression, an indication for differentiation, in a melanoma cell line [68]. ROSI also caused reversal of epithelial-mesenchymal transition in anaplastic thyroid cancer cell lines and increased expression of thyroglobulin, TSH receptor, sodium-iodide symporter, and thyroperoxidase mRNA [69]. CIGLI induced brain tumor stem cell differentiation [70]. In cultures of metaplastic urothelial cells, differentiation markers were increased after treatment with TRO [71].

### 5.3. TZD Effects in Animal Studies

PIO prevented lung tumor development in carcinogen-induced mouse models [72]. In a similar manner, PIO protected rats against chemically-induced (diethylnitrosamine and acetylaminofluorene) hepatocarcinogenesis [73]. PPAR\(\gamma\) could play a tumor-promoting role in hepatoma, because expression is significantly reduced in hepatocellular carcinoma with poor prognosis [74]. A similar situation is seen in endometrium, where benign lesions show strong PPAR\(\gamma\) immunoreactivity but malignant lesions low to absent PPAR\(\gamma\) expression [12]. Chemoprevention of endometrial cancer by ROSI was observed in PTEN heterozygous mice [75]. Increased PPAR\(\gamma\) expression was predominantly seen in less invasive oral squamous cancer [76]. Chemically-induced oral squamous carcinoma in rats was reduced by 40% through administration of PIO [77] and tongue carcinoma formation was reduced by 40% by TRO [78].

On the other hand, tumor-promoting effects of PIO were observed in the APC\(\min\) murine colon cancer model [41]. Because tumor-promoting effects were not seen in all cancer models, a model-specific effect cannot be excluded. The complex and, in part, opposing effects of TZDs on cancer development and progression can be explained by their cell-specific and species-specific action (tumor cells versus tumor environment). Effects of TZDs on immune cells may be the reason for the tumor-promoting effect of PIO in the APC\(\min\) mouse model and the reduced tumor growth in immune-compromised mice and in the azoxymethane-induced tumor model [79]. While PPAR\(\gamma\) activation may decrease proliferation of tumor cells, it may increase macrophage polarization towards the M2 phenotype (TAM) and induce anti-inflammatory effects, also mediated by PPAR\(\gamma\) activation (see Section 3).

### 5.4. Human Data

One phase II trial on prevention of lung, head, and neck carcinoma in 21 patients with oral leukoplakia using PIO has been completed. Fifteen patients showed partial responses, 2 stable disease and 4 patients had progressive disease (NCT00099021; http://www.cancer.gov/clinicaltrials/). Based on these promising results, another trial on prevention of lung cancer is recruiting patients (NCT00780234; http://www.cancer.gov/clinicaltrials/).

In human trials, no general correlation of the protective effect of PPAR\(\gamma\) expression against tumor progression and...
chemopreventive effects of TZDs was obvious. While a protective role of PPARy expression was postulated in breast tumors and TZDs also acted preventive on the development of breast cancer in humans, the chemopreventive effect on colon cancer was not consistent with a protective role of PPARy expression in tumor samples.

6. Combined Treatments of TZDs with Other Drug Compounds

6.1. In Vitro Studies. Several studies evaluated the effect of combined therapies with TZDs and other agents. A large variety of combinations of TZDs have been evaluated in vitro. The observed antitumor effects include cytotoxicity/decrease of cell viability, growth inhibition, and apoptosis (for overview see Table 3).

In combination treatment with RXR-α ligands, increased cellular differentiation was reported [80, 81]. Some combined therapies take advantage of the cross-talk of PPARy with other signaling pathways. For instance, the upregulation of PTEN by ROSI rendered hepatoma cells more sensitive to the action of 5-fluorouracil [82]. Based on the idea of cross-talk between the ERK and PPARy pathways, combinations of ERK inhibitors and PPARy agonists could be useful in tumors with deleterious elevation of PPARy. Experimental data corroborate such an idea: gefitinib and ROSI increased growth inhibition of lung cancer cells and increased PPARy and PTEN expression [83]. Herceptin, an antibody against the EGF-receptor HER2, sensitized breast cancer cells for the differentiating action of TRO [84].

6.2. Animal Studies. The following examples show that improved antitumor responses were also obtained in vivo: growth of lung carcinoma xenografts and of chemically-induced breast tumors was inhibited by a combination of ROSI and platinum-based compounds [85, 86]. ROSI in combination with suberoylanilidehydroxamic acid (SAHA) decreased progression of preinvasive lung cancer in a murine model by 77% [46]. Similarly, a combination of TRO and platinum-based compounds increased survival of mesothelioma-xenografted mice [87]. The combination of EFA and paclitaxel reduced the size of anaplastic thyroid carcinoma xenografts [88]. Progression of ovarian carcinoma xenografts was slower when a combination of CIGLI and cisplatin was administered. Synergistic effects were reduction of angiogenesis and increased proapoptotic effects [89]. Aerosolized budesonide and oral PIO decreased lung cancer mass by 90% in a benz(a)pyrene-induced murine lung cancer model [90].

6.3. Human Data. Phase II trials of combination with the COX-2 inhibitor rofecoxib and PIO were able to induce complete response, partial responses, or stable disease in 5/5 angiosarcoma, 1/1 hemangoendothelioma, 4/19 metastatic melanoma, 10/40 soft tissue sarcoma, and 4/14 glioma patients [59, 91, 92]. Combination of PIO with other chemotherapeutic drugs induced one complete response and prolonged disease-free survival in 2 of 19 patients with advanced melanoma enrolled in this phase II trial [91]. These data suggest potential efficacy of TZDs combined with other compounds in melanoma. For further evaluation of comedication with TZDs in patients, a prospective phase I/II trial of PIO combined with lenalidomide, dexamethasone, and treosulfan (NCT01614301) is currently recruiting patients (http://www.cancer.gov/clinical trials/).

According to human trials, only soft tissue sarcoma and melanoma might be sensitive to combinations of TZDs and COX-2 inhibitors and TZDs in polytherapy, respectively.

7. Specific Role of TZDs in Differentiated Thyroid Carcinoma (DTC)

PPARy has a specific role in thyroid cancer because follicular thyroid cancer is the only known neoplasm to be associated with a PPARy fusion gene product [93]. PAX8/PPARy is expressed in 30–35% of follicular thyroid carcinoma and 2–13% of follicular adenomas [94]. This chimeric protein is the result of a genetic translocation between chromosomes 2 and 3 and can activate the PPARy response element and induce proliferation. The mutation acts both as a gain and loss of function mutant in thyroid cancer and determines thyroid tumor differentiation; in more aggressive tumors gain of function predominates [93].

Thyroid cancer incidence in the United States has increased in the last thirty years not only apparently because of enhanced detection but probably also as a true increase [95]. DTC is the most common type of thyroid carcinoma, mainly in the form of papillary thyroid carcinoma, accounting for 80–90% of all thyroid cancer cases. The second-most common form of DTC is follicular thyroid cancer with 10–15% incidence. The prognosis of DTC is generally good, with a 10-year survival rate of 85% [96]. A total of 10–20% of patients develops distant metastases [97]. In this group, the 10-year survival rate drops to 40%. Recurrence in DTC, however, occurs in up to a third of patients and only 30% of patients with distant metastases respond to radioiodine (RAI) therapy with complete remission [98, 99]. First-line treatment of DTC is by total or near total removal of the thyroid and if necessary lymph node dissection (Figure 3). This is generally followed by RAI treatment for thyroid remnant ablation and elimination of metastases. In case of insufficient efficacy of this treatment, doxorubicin is initiated [100]. Because doxorubicin treatment is not highly efficient, it is expected that, in the future, differentiating therapies will play a prominent role in cancer treatment. Redifferentiating compounds include retinoids, histone deacetylase inhibitors, DNA methyltransferase inhibitors, and TZDs. Somatostatin analogues such as 68 Ga-DOTATOC are additional options for RAI-negativ thyroid cancer [101].

PIO and CIGLI did not increase differentiation in a study on the human papillary carcinoma cell line NPA [102]. In another, TRO, ROSI, and PIO showed antiproliferative, proapoptotic, and differentiating effects on DTC cells [103]; TRO could increase expression of sodium-iodide symporter in DTC lines [104] and restore radioiodine-uptake in vitro [105].
| TZD Additional compound | Model | Effect | Reference |
|------------------------|-------|--------|-----------|
| Gamma-radiation        | Lung carcinoma cell lines (A549, H460) | DNA damage, apoptosis | [124] |
| RXR-α ligands (SR11237, 6-OH-11-O-hydroxyphenanthrene) | Breast carcinoma cell line (MDA-MB-231), lung carcinoma cell line (Calu-3), glioblastoma cell line (U87MG), melanoma cell line (G361) | Growth inhibition; apoptosis | [125–127] |
| CIFCL | Ovarian cancer cell line (HEY) | Decrease of proliferation | [128] |
| Ciglialtin | Pancreatic carcinoma cell lines (Panc02, MIA, PAcA-2), breast carcinoma cell lines (EMT6, MDA-MB-316), colon cancer cell line (C26) | Decrease of cell viability; decrease of proliferation | [129] |
| Phenylbutyrate | Lung carcinoma cell lines (A549, H157) | Growth inhibition | [130] |
| 9-cis retinoic acid | Gastric carcinoma cell line (SGC7901) | Apoptosis | [131] |
| Cisplatin | Lung cancer cell lines (A549, H522); mesotheloma cell line (EHMES-10) | Growth inhibition | [87, 132] |
| Paclitaxel | Lung carcinoma cell lines (A549, H522) | Growth inhibition | [132] |
| RXR-α ligands (bexarotene, all-trans retinoic acid) | Breast cancer cell lines (MCF-7, T-47D, ZR-75-1) | Growth inhibition | [133] |
| TRO Cell signalling molecules (TRAIL, hergulin) | Ovarian cancer cell line (HEY); breast cancer cell lines (MCF-7, SKBR-3, MDA-MB-453) | Decrease of cell number; apoptosis | [128, 134] |
| Lovastatin | Glioblastoma cell line (DBTRG05MG), lung cancer cell line (CL1-0) | Cell cycle inhibitor expression | [135] |
| Aspirin | Lung cancer cell lines (CL1-0, A549) | Decrease of proliferation | [136] |
| Tamoxifen | Breast cancer cell line (MCF-7) | Growth inhibition | [137] |
| X-rays | Cervix cancer cell lines (HeLa, Me180) | Decrease of cell viability | [138] |
| Platinium-based compounds (cisplatin, carboplatin) | Ovarian cancer cell lines (OVCA420, OVCA429, ES), lung cancer cell lines (A549, Calu-1, H23, H596, HI650) | Growth inhibition | [85] |
| 5-Fluorouracil | Hepatoma cell lines (BEL7402, Huh-7); colon cancer cell line (HT-29) | Decrease of cell viability, apoptosis | [82, 139] |
| RXR-α ligands (bexarotene, 9-cis retinoic acid) | Breast cancer cell lines (MCF-7TR1, SKBR-3, T47D), colon cancer cell line (Moser) | Increase of differentiation, growth inhibition; decrease of cell viability | [80, 140] |
| ROSI Cell signalling molecules (TNF-α, anti-Fas IgM, Seliciclib) | Breast cancer cell line (MDA-MB-231) | Growth inhibition | [141] |
| Gemcitabine | Pancreas cancer cell lines (PANC-1, Panc02) | Decrease of cell viability, growth inhibition | [142] |
| Gefitinib | Lung cancer cell line (A549) | Growth inhibition | [83] |
| Herceptin | Breast cancer cell line (MCF-7) | Growth inhibition | [84] |
| Bortezomib | Melanoma cell lines (MV3, FemX-1, G361) | Growth inhibition | [143] |
| PIO Paclitaxel | Lung cancer cell lines (A549, H522) | Growth inhibition | [132] |
| RXR-α ligands (LG268) | Liposarcoma cells (primary) | Increase of differentiation | [81] |
| Statins (Simvastatin, lovastatin) | Glioblastoma cell lines (U87, U138, LN405, RGII); meningoeoma cell lines (IOMM-Lee, KT21-MGI) | Decrease of cell viability | [144, 145] |
| Gemcitabine | Pancreas cancer cell line (PANC-1) | Decrease of cell viability | [142] |
| 2-Deoxyglucose | Prostate cancer cell lines (PC-3, LNCaP) | Decrease in tumor spheroid formation | [146] |
| EFA Paclitaxel | Anaplastic thyroid carcinoma cell lines (DRO, BHT-101, ARO) | Growth inhibition | [88] |
enrolled in a pilot study [111]. In another pilot study, ROSI treatment with ROSI was obtained in one of five patients of this treatment. Evidence for increased RAI-uptake upon thyroglobulin levels and tumor size indicated partial success a clinical trial showed increased RAI-uptake in therapeutic treatment resulted in positive RAI scans in 4/10 patients and noniodide avid metastases of DTC [109, 110]. Decreased of RAI-uptake after treatment with ROSI in a patient with seen [108]. Two case reports described successful induction with PIO for 6 months, no increase in RAI-uptake was seen [106]. ROSI was also able to lack of uptake in the lower part of the right lobe (upper right).

7.1. Animal Studies. PIO was effective in reducing metastatic disease in a tumor model where the effect of PAX8/PPARγ fusion protein is mimicked [106]. ROSI was also able to reduce thyrocyte growth by 40% in a murine knock-in model of thyroid hormone receptor β [107].

7.2. Human Data. In a small cohort of 5 patients treated with PIO (upper left) and scintigraphy with 123I iodide showing lack of uptake in the lower part of the right lobe (upper right).

Figure 3: Overview of treatment options for DTC. Scheme of thyroid tumor (upper left) and scintigraphy with 123I Iodine showing lack of uptake in the lower part of the right lobe (upper right).

8. Conclusion

Current data do not suggest a correlation of clinical efficacy and high PPARγ expression according to mRNA and protein expression in tumor samples. This lack of relation could be due to methodical problems of PPARγ detection in archived tumor samples and in the complexity of TZD action. First, TZDs show a variety of genomic and nongenomic effects and several antitumor effects occur independent of PPARγ. This is particularly obvious in experiments where combination of PPARγ agonists and antagonists act synergistically on inhibition of proliferation [116]. Cell specific effects of TZDs are particularly important in cancer because their action on immune cells may antagonize their effects on tumor cells. This suggests that administration of TZDs after tumor initiation may be inefficient or even deleterious and could explain why cancer mortality was increased in the meta-analysis of cancer incidence in patients with TZD treatment. Species-specific action was reported between human and murine endothelial cells where increase of proliferation was seen in the mouse cells and an antiproliferative effect in human cells [117]. Furthermore, TZDs show compound-specificity. TRO and CIGLI acted as antiproliferatives on ovarian cancer cell lines, while ROSI and PIO did not. This could be due to additional targets and/or PPARγ independent effects; TRO for instance has stronger Akt/mTOR activity than the other TZDs. Finally, the effect of TZDs is concentration-dependent. Low concentrations of TZDs induced cell cycle arrest, while higher doses (>100 μM) caused apoptosis. Effects at higher concentrations can be explained by transactivation of PPARγ by cross-talk between signaling pathways where one receptor activates a receptor for a different ligand. Alternatively, TZDs may activate a specific subunit within a receptor oligomer [118]. As to the concentration, other coactivators may be involved in the effect and different downstream processes may be activated. PPARγ agonists can also change the cell's expression of PPARγ to different extents.

Against the background of limitations of traditional as well as new (transgenic) mouse models [119, 120] for human cancer, only efficacy in human trials is included in our final assessment. Use of TZDs in cancer might be therapeutic in prostate cancer and glioma, chemopreventive in colon, lung, and breast cancer, and increase therapeutic efficacy combined with other therapies in thyroid cancer, soft tissue sarcoma, and melanoma.

Conflict of Interests

The authors declare that there is no conflict of interests.

References

[1] S. Malik, P. K. Upadhyaya, and S. Miglani, “Thiazolidinediones: a plethora of biological load,” International Journal of PharmTech Research, vol. 3, no. 1, pp. 62–75, 2011.

[2] J. Youssed and M. Badr, “PPAR ligands,” in Peroxisome Proliferator-Activated Receptors: Discovery and Recent Advances, J. Youssed and M. Badr, Eds., Springer Science+Business Media, New York, NY, USA, 2013.
[32] G. D. Demetri, C. D. Fletcher, E. Mueller et al., "Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 7, pp. 3951–3956, 1999.

[33] G. Debrock, V. Vanhentenriek, R. Sciot, M. Debiec-Rychter, R. Oven, and A. van Oosterom, "A phase II trial with rosiglitazone in liposarcoma patients," *British Journal of Cancer*, vol. 89, no. 8, pp. 1409–1412, 2003.

[34] Y. Dai and W. H. Wang, "Peroxisome proliferator-activated receptor gamma and colorectal cancer," *World Journal of Gastrointestinal Oncology*, vol. 2, no. 3, pp. 159–164, 2010.

[35] M. Pancione, N. Forte, L. Sabatino et al., "Reduced β-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome," *Human Pathology*, vol. 40, no. 5, pp. 714–725, 2009.

[36] S. Theocharis, C. Giaginis, A. Parasi et al., "Expression of peroxisome proliferator-activated receptor-γ in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival," *Digestive Diseases and Sciences*, vol. 52, no. 9, pp. 2305–2311, 2007.

[37] A. Gustafsson, E. Hansson, U. Kressner et al., "EPI-4 subtype, COX and PPARy receptor expression in colorectal cancer in prediction of disease-specific mortality," *International Journal of Cancer*, vol. 121, no. 2, pp. 232–240, 2007.

[38] C. A. McAlpine, Y. Barak, I. Matise, and R. T. Cormier, "Intestinal-specific PPARy deficiency enhances tumorigenesis in ApcMin/+ mice," *International Journal of Cancer*, vol. 119, no. 10, pp. 2339–2346, 2006.

[39] E. Osawa, A. Nakajima, K. Wada et al., "Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice," *Gastroenterology*, vol. 124, no. 2, pp. 361–367, 2003.

[40] T. Yoshizumi, T. Ohta, I. Ninomiya et al., "Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects," *International Journal of Oncology*, vol. 25, no. 3, pp. 631–639, 2004.

[41] I. K. Choi, Y. H. Kim, J. S. Kim, and J. H. Seo, "PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo," *Investigational New Drugs*, vol. 26, no. 3, pp. 283–288, 2008.

[42] T. Tsukahara and H. Haniu, "Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells," *Biochemical and Biophysical Research Communications*, vol. 424, no. 3, pp. 524–529, 2012.

[43] M. H. Kulke, G. D. Demetri, N. E. Sharpless et al., "A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer," *Cancer Journal*, vol. 8, no. 5, pp. 395–399, 2002.

[44] S. Theocharis, H. Kaneli, E. Politis et al., "Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade," *Lung Cancer*, vol. 36, no. 3, pp. 249–255, 2002.

[45] H. Sasaki, M. Tanahashi, H. Yukiue et al., "Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer," *Lung Cancer*, vol. 36, no. 1, pp. 71–76, 2002.

[46] C. M. Lyon, D. M. Klinge, K. C. Do et al., "Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model," *Carcinogenesis*, vol. 30, no. 12, pp. 2095–2099, 2009.

[47] W. G. Jiang, A. Douglas-Jones, and R. E. Mansel, "Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARγ co-activator, PGC-1, in human breast cancer correlates with clinical outcomes," *International Journal of Cancer*, vol. 106, no. 5, pp. 752–757, 2003.

[48] G. Magenta, X. Borenstein, R. Rolando, and M. A. Jasnis, "Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3," *BMC Cancer*, vol. 8, article 47, 2008.

[49] B. Bojková, M. Garajová, K. Kajo et al., "Pioglitazone in chemically induced mammary carcinogenesis in rats," *European Journal of Cancer Prevention*, vol. 19, no. 5, pp. 379–384, 2010.

[50] H. J. Burstien, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, "Use of the peroxisome proliferator-activated receptor (PPARγ) ligand troglitazone as treatment for refractory breast cancer: a phase II study," *Breast Cancer Research and Treatment*, vol. 79, no. 3, pp. 391–397, 2003.

[51] L. D. Yee, N. Williams, P. Wen et al., "Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers," *Clinical Cancer Research*, vol. 13, no. 1, pp. 246–252, 2007.

[52] Y. Nakamura, T. Suzuki, A. Sugawara, Y. Arai, and H. Sasano, "Peroxisome proliferator-activated receptor gamma in human prostate carcinoma," *Pathology International*, vol. 59, no. 5, pp. 288–293, 2009.

[53] J.-S. Annicotte, I. Iankova, S. Miard et al., "Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer," *Molecular and Cellular Biology*, vol. 26, no. 20, pp. 7561–7574, 2006.

[54] E. Mueller, M. Smith, P. Sarraf et al., "Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 20, pp. 10990–10995, 2000.

[55] J. I. Hisatake, T. Ikezoe, M. Carey, S. Holden, S. Tomoyasu, and H. P. Koeffler, "Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer," *Cancer Research*, vol. 60, no. 19, pp. 5494–5498, 2000.

[56] M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, "Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines," *Japanese Journal of Cancer Research*, vol. 93, no. 6, pp. 660–666, 2002.

[57] C. Grommes, D. S. Conway, A. Alshekheile, and J. S. Barnholtz-Sloan, "Inverse association of PPARγ agonists use and high grade glioma development," *Journal of Neuro-Oncology*, vol. 100, no. 2, pp. 233–239, 2010.

[58] C. Grommes, J. C. Karlo, A. Caprariello, D. Blankenship, A. Dechant, and G. E. Landreth, "The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model," *Cancer Chemotherapy and Pharmacology*, vol. 71, no. 4, pp. 929–936, 2013.

[59] P. Hau, L. Kunz-Schughart, U. Bogdahn et al., "Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study," *Oncology*, vol. 73, no. 1-2, pp. 21–25, 2007.
M. Monami, I. Dicembrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014.

M. Kato, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002.

M. Paraman, D. Eurombrini, and E. Mannucci, “Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials,” Acta Diabetologica, vol. 51, no. 1, pp. 91–101, 2014.

S. Kawa, T. Nikiado, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002.

M. Kato, T. Kusumi, S. Tsuchida, M. Tanaka, M. Sasaki, and H. Kujo, “Induction of differentiation and peroxisome proliferator-activated receptor y expression in cancer colon cell lines by troglitazone,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 2, pp. 73–79, 2004.

I. Jagan, A. Fatehullah, R. K. Deevi, V. Bingham, and F. C. Campbell, “Rescue of glandular dysmorphogenesis in PTEN-deficient colorectal cancer epithelium by PPARγ targeted therapy,” Oncogene, vol. 32, no. 10, pp. 1305–1315, 2013.

Y. Li, Y. Meng, H. Li et al., “Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand resiglitazone in human melanoma cell line A375,” Medical Oncology, vol. 23, no. 3, pp. 393–402, 2006.

A. Aiello, G. Pandini, F. Frasca et al., “Peroxisomal peroxisome proliferator-activated receptor γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006.

E. Pesteireva, S. Kanakasabai, and J. B. Bright, “PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells,” British Journal of Cancer, vol. 106, no. 10, pp. 1702–1712, 2012.

C. L. Varley, J. Thalhischmidt, B. Smith, M. Stower, and J. Southgate, “Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces terminal differentiation in normal human urothelial cells,” The American Journal of Pathology, vol. 164, no. 5, pp. 1789–1798, 2004.

M.-Y. Li, A. W. Y. Kong, H. Yuan et al., “Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice,” Current Cancer Drug Targets, vol. 12, no. 6, pp. 597–606, 2012.

I. Borbath, I. Leclercq, P. Moulin, C. Sempoux, and Y. Hornsman, “The PPARγ agonist pioglitazone inhibits early neoplastic occurrence in the rat liver,” European Journal of Cancer, vol. 43, no. 11, pp. 1755–1763, 2007.

J. Yu, L. Qiao, L. Zimmermann et al., “Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo,” Hepatology, vol. 43, no. 1, pp. 134–143, 2006.

W. Wu, J. Celestino, M. R. Milam et al., “Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model,” International Journal of Gynecological Cancer, vol. 18, no. 2, pp. 329–338, 2008.

S. Theocaris, J. Klijianienko, C. Giaginis et al., “Peroxisome proliferator-activated receptor-y in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 2, pp. 251–259, 2011.

R. Suzuki, H. Kohno, M. Suzuki et al., “An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies,” Carcinogenesis, vol. 27, no. 3, pp. 619–630, 2006.

K. Yoshida, Y. Hirose, T. Tanaka et al., “Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor γ ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide,” Cancer Science, vol. 94, no. 4, pp. 365–371, 2003.

H. Li, A. L. Sorenson, J. Poczobut et al., “Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis,” PLoS ONE, vol. 6, no. 12, Article ID e28133, 2011.

D. Bonfiglio, E. Cione, H. Qi et al., “Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells,” The American Journal of Pathology, vol. 175, no. 3, pp. 1270–1280, 2009.

P. Tontonoz, S. Singer, B. M. Forman et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor y and the retinoid X receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 237–241, 1997.

L. Q. Cao, X. L. Wang, Q. Wang et al., “Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway,” Acta Pharmacologica Sinica, vol. 30, no. 9, pp. 1316–1322, 2009.

S. Y. Lee, G. Y. Hur, K. H. Jung et al., “PPARγ agonist increase gefitinib’s antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2009.

Z. Yang, R. Bagheri-Yarmad, S. Balasenthil et al., “HER2 regulation of peroxisome proliferator-activated receptor γ expression and sensitivity of breast cancer cells to PPARγ ligand therapy,” Clinical Cancer Research, vol. 9, no. 8, pp. 3198–3203, 2003.

D. G. Girnu, E. Naseri, S. B. Vafai et al., “Synergy between PPARγ ligands and platinum-based drugs in cancer,” Cancer Cell, vol. 11, no. 5, pp. 395–406, 2007.

K. Tikoo, P. Kumar, and J. Gupta, “Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7,12-dimethyl benzaanthracene (DMBA) induced breast cancer rats,” BMC Cancer, vol. 9, article 107, 2009.

N. Hamaguchi, H. Hamada, S. Miyoshi et al., “In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth,” Cancer Science, vol. 101, no. 9, pp. 1955–1964, 2010.

J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIPI,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006.

Y. Yokoyama, B. Xin, T. Shigeto, and H. Mizunuma, “Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth
of human ovarian cancers,” *Journal of Cancer Research and Clinical Oncology*, vol. 137, no. 8, pp. 1219–1228, 2011.

[90] H. Fu, J. Zhang, J. Pan et al., “Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice,” *Molecular Carcinogenesis*, vol. 50, no. 12, pp. 913–921, 2011.

[91] A. Reichle, K. Bross, T. Vogt et al., “Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma,” *Cancer*, vol. 101, no. 10, pp. 2247–2256, 2004.

[92] T. Vogt, C. Hafner, K. Bross et al., “Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors,” *Cancer*, vol. 98, no. 10, pp. 2251–2256, 2003.

[93] F. Ondrey, “Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications For Chemoprevention,” *Clinical Cancer Research*, vol. 15, no. 1, pp. 2–8, 2009.

[94] O. Omur and Y. Baran, “An update on molecular biology of thyroid cancers,” *Critical Reviews in Oncology/Hematology*, vol. 90, no. 3, pp. 233–252, 2014.

[95] N. Li, X. L. Du, L. R. Reitzel, L. Xu, and E. M. Sturgis, “Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008,” *Thyroid*, vol. 23, no. 1, pp. 103–110, 2013.

[96] C. F. A. Eustatia-Rutten, E. P. M. Corssmit, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. W. Smits, “Survival and death causes in differentiated thyroid carcinoma,” *Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 1, pp. 313–319, 2006.

[97] C. Durante, N. Haddy, E. Baudin et al., “Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy,” *Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 8, pp. 2892–2899, 2006.

[98] O. Dobán, A. De La Vieja, V. Paroder et al., “The sodium/iodide symporter (NIS): characterization, regulation, and medical significance,” *Endocrine Reviews*, vol. 24, no. 1, pp. 48–77, 2003.

[99] M. J. Schlumberger, “Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status,” *Journal of Endocrinological Investigation*, vol. 22, no. 11, pp. 3–7, 1999.

[100] T. Carling and R. Udelsman, Eds., *Thyroid Tumors*, Lippincott Williams & Wilkins, Philadelphia, PA, USA, 9th edition, 2011.

[101] A. Versari, M. Sollini, A. Frasoldati et al., “Differentially thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients,” *Thyroid*, vol. 24, no. 4, pp. 715–726, 2014.

[102] M. L. Martelli, R. Iuliano, I. Le Pera et al., “Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth,” *Journal of Clinical Endocrinology and Metabolism*, vol. 87, no. 10, pp. 4728–4735, 2002.

[103] E. Fröhlich, P. Brossart, and R. Wahl, “Induction of iodide uptake in transformed thyocytes: a compound screening in cell lines,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 36, no. 5, pp. 780–790, 2009.

[104] J.-W. Park, R. Zarnegar, H. Kanauchi et al., “Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines,” *Thyroid*, vol. 15, no. 3, pp. 222–231, 2005.

[105] E. Fröhlich, F. Machicao, and R. Wahl, “Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyocytes in culture,” *Endocrine-Related Cancer*, vol. 12, no. 2, pp. 291–303, 2005.

[106] M. E. Dobson, E. Diale-Krou, V. Grachtchouk et al., “Pioglitazone induces a proapoptotic antitumor response in mice with PAX8-PPARγ fusion protein thyroid carcinoma,” *Endocrinology*, vol. 152, no. 11, pp. 4455–4465, 2011.

[107] Y. Kato, H. Ying, L. Zhao et al., “PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway,” *Oncogene*, vol. 25, no. 19, pp. 2736–2747, 2006.

[108] S. J. Rosenbaum-Krumme, A. Bockisch, and J. Nagarajah, “Pioglitazone therapy in progressive differentiated thyroid carcinoma,” *NuklearMedizin*, vol. 51, no. 4, pp. 111–115, 2012.

[109] M. Elola, A. Yoldı, J. I. Emparanza, T. Matteucci, I. Bilbao, and M. Goena, “Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioactive iodine uptake,” *Revista Espanola de Medicina Nuclear*, vol. 30, no. 4, pp. 241–243, 2011.

[110] A. N. Elias and P. Lizotte, “Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone,” *Clinical Nuclear Medicine*, vol. 31, no. 9, pp. 517–519, 2006.

[111] J.-C. Philips, C. Petite, J.-P. Willi, F. Buchegger, and C. A. Meier, “Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers,” *Nuclear Medicine Communications*, vol. 25, no. 12, pp. 1183–1186, 2004.

[112] E. Kebebew, M. Peng, E. Reiff et al., “A phase II trial of rosiglitazone therapy,” *Critical Reviews in Oncology/Hematology*, vol. 45, no. 2, pp. 228–233, 2002.

[113] S. Tepmongkol, S. Keelawat, S. Honsawek, and P. Ruangvejvorachai, “Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” *Surgery*, vol. 140, no. 6, pp. 960–967, 2006.

[114] S. Tepmongkol, S. Keelawat, S. Honsawek, and E. F. Greenspan, “Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer,” *Thyroid*, vol. 19, no. 9, pp. 953–956, 2009.

[115] E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” *European Journal of Cancer*, vol. 45, no. 2, pp. 228–247, 2009.

[116] J. D. Burton, D. M. Goldenberg, and R. D. Blumenthal, “Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types,” *PPAR Research*, vol. 2008, Article ID 494161, 7 pages, 2008.

[117] S. Kakiuchi-Kiyota, J. A. Vetro, S. Suzuki et al., “Effects of the PPARγ agonist troglitazone on endothelial cells in vivo and in vitro: Differences between human and mouse,” *Toxicology and Applied Pharmacology*, vol. 237, no. 1, pp. 83–90, 2009.

[118] S. Takano, T. Kubota, H. Nishibori et al., “Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis,” *Anticancer Research*, vol. 28, no. 6, pp. 3593–3599, 2008.
M. De Jong and T. Maina, "Of mice and humans: are they the same?—Implications in cancer translational research," Journal of Nuclear Medicine, vol. 51, no. 4, pp. 501–504, 2010.

V. Vaish, L. Tanwar, and S. N. Sanyal, "The role of NF-κB and PPAR in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors," Tumour Biology, vol. 31, no. 5, pp. 427–436, 2010.

M. V. Pino, M. F. Kelley, and Z. Jayyosi, "Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist," Toxicologic Pathology, vol. 32, no. 1, pp. 58–63, 2004.

H. Kohno, S. Yoshitani, S. Takashima et al., "Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats," Japanese Journal of Cancer Research, vol. 92, no. 4, pp. 396–403, 2001.

E. J. Han, C. N. Im, S. H. Park, E. Y. Moon, and S. H. Hong, "Combined treatment with peroxisome proliferator-activated receptor (PPAR) gamma ligands and gamma radiation induces apoptosis by PPARγ-independent up-regulation of reactive oxygen species-induced deoxyribonucleic acid damage signals in non-small cell lung cancer cells," International Journal of Radiation Oncology Biology Physics, vol. 85, no. 5, pp. e239–e248, 2013.

S. Y. James, F. Lin, S. K. Kolluri, M. I. Dawson, and X.-K. Zhang, "Regulation of retinoic acid receptor β expression by peroxisome proliferator-activated receptor γ ligands in cancer cells," Cancer Research, vol. 63, no. 13, pp. 3531–3538, 2003.

A. Papi, P. Rochhi, A. M. Ferreri, F. Guerra, and M. Orlandi, "Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells," Oncology Reports, vol. 21, no. 4, pp. 1083–1089, 2009.

A. Papi, L. Tatenhorst, D. Terwel et al., "PPARγ and RXRγ ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models," Journal of Neurochemistry, vol. 109, no. 6, pp. 1779–1790, 2009.

K. Bräutigam, J. Biernath-Wüpping, D. O. Bauschlag et al., "Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 5, pp. 875–886, 2011.

P. Mrówka, E. Główkowska, D. Nowis et al., "Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin," International Journal of Oncology, vol. 32, no. 1, pp. 249–255, 2008.

T. H. Chang and E. Szabo, "Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung," Clinical Cancer Research, vol. 8, no. 4, pp. 1206–1212, 2002.

Y. Liu, Z.-A. Zhu, S.-N. Zhang et al., "Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro," Tumor Biology, vol. 34, no. 4, pp. 2409–2418, 2013.

R. C. Reddy, A. Srirangam, K. Reddy et al., "Chemotherapeutic drugs induce PPARγ expression and show sequence-specific synergy with PPARγ ligands in inhibition of non-small cell lung cancer," Neoplasia, vol. 10, no. 6, pp. 597–603, 2008.

E. Elstner, E. A. Williamson, C. Zang et al., "Novel therapeutic approach: ligands for PPARγ and retinoid receptors induce apoptosis in bel-2-positive human breast cancer cells," Breast Cancer Research and Treatment, vol. 74, no. 2, pp. 155–165, 2002.

B.-H. Park, S.-B. Lee, D. B. Stolz, Y. J. Lee, and B.-C. Lee, "Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-γ (PPARγ) agonist in breast cancer cells," Journal of Biological Chemistry, vol. 286, no. 22, pp. 20087–20099, 2011.

C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, and S.-E. Chuang, "Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone," International Journal of Cancer, vol. 118, no. 3, pp. 773–779, 2006.

K.-H. Yan, C.-J. Yao, H.-Y. Chang, G.-M. Lai, A.-L. Cheng, and S.-E. Chuang, "The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells," Molecular Cancerigenesis, vol. 49, no. 3, pp. 235–246, 2010.

H.-N. Yu, E.-M. Noh, Y.-R. Lee et al., "Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells," Biochemical and Biophysical Research Communications, vol. 377, no. 1, pp. 242–247, 2008.

Z. An, X. Liu, H. Song et al., "Effect of troglitazone on radiation sensitivity in cervix cancer cells," Radiation Oncology Journal, vol. 30, no. 2, pp. 78–87, 2012.

Y.-Q. Zhang, X.-Q. Tang, L. Sun et al., "Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor γ," World Journal of Gastroenterology, vol. 13, no. 10, pp. 1534–1540, 2007.

R. M. Cesario, J. Stone, W.-C. Yen, R. P. Bissonnette, and W. W. Lamph, "Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer," Cancer Letters, vol. 240, no. 2, pp. 225–233, 2006.

M. Mody, N. Dharker, M. Bloomston et al., "Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-α, CHI11 and CYC202," Endocrine-Related Cancer, vol. 14, no. 2, pp. 305–315, 2007.

H. Koga, K. Selvendiran, R. Sivakumar et al., "PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells," International Journal of Oncology, vol. 40, no. 3, pp. 679–685, 2012.

C. Freudlsgerger, A. Thies, U. Pfüller, and U. Schumacher, "The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-γ agonist rosiglitazone in human melanoma cells," Anticancer Research, vol. 27, no. 1, pp. 207–213, 2007.

S. Gehring, J. H. Tapia-Pérez, E. Kirches et al., "Cytotoxic effects of statins and thiazolidinediones on meningioma cells," Journal of Neuro-Oncology, vol. 102, no. 3, pp. 383–393, 2011.

J. H. Tapia-Pérez, E. Kirches, C. Mawrin, R. Firsching, and T. Schneider, "Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells," Cancer Chemotherapy and Pharmacology, vol. 67, no. 5, pp. 1193–1201, 2011.

E. Gottfried, S. Rogenhofer, H. Wabel et al., "Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids," Cancer Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 117–126, 2011.